{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:12:28Z","timestamp":1780449148498,"version":"3.54.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:00:00Z","timestamp":1675382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:00:00Z","timestamp":1675382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Paula and Rodger Riney Foundation (K.Anderson) The Adelson Medical Research Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Novel drug discoveries have shifted the treatment paradigms of most hematological malignancies, including multiple myeloma (MM). However, this plasma cell malignancy remains incurable, and novel therapies are therefore urgently needed. Whole-genome transcriptome analyses in a large cohort of MM patients demonstrated that alterations in pre-mRNA splicing (AS) are frequent in MM. This manuscript describes approaches to identify disease-specific alterations in MM and proposes RNA-based therapeutic strategies to eradicate such alterations. As a \u201cproof of concept\u201d, we examined the causes of aberrant HMMR (Hyaluronan-mediated motility receptor) splicing in MM. We identified clusters of single nucleotide variations (SNVs) in the HMMR transcript where the altered splicing took place. Using bioinformatics tools, we predicted SNVs and splicing factors that potentially contribute to aberrant HMMR splicing. Based on bioinformatic analyses and validation studies, we provided the rationale for RNA-based therapeutic strategies to selectively inhibit altered HMMR splicing in MM. Since splicing is a hallmark of many cancers, strategies described herein for target identification and the design of RNA-based therapeutics that inhibit gene splicing can be applied not only to other genes in MM but also more broadly to other hematological malignancies and solid tumors as well.<\/jats:p>","DOI":"10.1038\/s41408-023-00791-0","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T05:14:20Z","timestamp":1675401260000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics"],"prefix":"10.1038","volume":"13","author":[{"given":"Daisuke","family":"Ogiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Chyra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigitas J.","family":"Verselis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"O\u2019Keefe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacquelyn","family":"Cobb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivane","family":"Abiatari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanth","family":"Talluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjana Anilkumar","family":"Sithara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teru","family":"Hideshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6955-6267","authenticated-orcid":false,"given":"Roman","family":"H\u00e1jek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Dorfman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda M.","family":"Pilarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-0886","authenticated-orcid":false,"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5704-6040","authenticated-orcid":false,"given":"Sophia","family":"Adamia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,3]]},"reference":[{"key":"791_CR1","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","volume":"132","author":"BA Walker","year":"2018","unstructured":"Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018;132:587\u201397.","journal-title":"Blood."},{"key":"791_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","volume":"33","author":"BA Walker","year":"2019","unstructured":"Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, et al. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019;33:159\u201370.","journal-title":"Leukemia."},{"key":"791_CR3","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature09837","volume":"471","author":"MA Chapman","year":"2011","unstructured":"Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471:467\u201372.","journal-title":"Nature."},{"key":"791_CR4","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3324\/haematol.2019.235424","volume":"106","author":"MA Bauer","year":"2021","unstructured":"Bauer MA, Ashby C, Wardell C, Boyle EM, Ortiz M, Flynt E, et al. Differential RNA splicing as a potentially important driver mechanism in multiple myeloma. Haematologica. 2021;106:736\u201345.","journal-title":"Haematologica."},{"key":"791_CR5","doi-asserted-by":"crossref","unstructured":"Wilkinson ME, Charenton C, Nagai K. RNA splicing by the spliceosome. Annu Rev Biochem. 2019;89:359\u201388.","DOI":"10.1146\/annurev-biochem-091719-064225"},{"key":"791_CR6","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/nrm.2017.86","volume":"18","author":"Y Shi","year":"2017","unstructured":"Shi Y. Mechanistic insights into precursor messenger RNA splicing by the spliceosome. Nat Rev Mol Cell Biol. 2017;18:655\u201370.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"791_CR7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrm3742","volume":"15","author":"AG Matera","year":"2014","unstructured":"Matera AG, Wang Z. A day in the life of the spliceosome. Nat Rev Mol Cell Biol. 2014;15:108\u201321.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"791_CR8","doi-asserted-by":"crossref","unstructured":"Grodecka L, Buratti E, Freiberger T. Mutations of Pre-mRNA splicing regulatory elements: are predictions moving forward to clinical diagnostics? Int J Mol Sci. 2017;18:1668.","DOI":"10.3390\/ijms18081668"},{"key":"791_CR9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3389\/fgene.2019.00278","volume":"10","author":"D Zhang","year":"2019","unstructured":"Zhang D, Duan Y, Cun J, Yang Q. Identification of prognostic alternative splicing signature in breast carcinoma. Front Genet. 2019;10:278.","journal-title":"Front Genet"},{"key":"791_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0115-2","volume":"8","author":"YT Yang","year":"2018","unstructured":"Yang YT, Chiu YC, Kao CJ, Hou HA, Lin CC, Tsai CH, et al. The prognostic significance of global aberrant alternative splicing in patients with myelodysplastic syndrome. Blood Cancer J. 2018;8:78.","journal-title":"Blood Cancer J"},{"key":"791_CR11","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.2217\/imt-2019-0058","volume":"11","author":"A Joshi","year":"2019","unstructured":"Joshi A, Tandel N, Tyagi P, Dalai SK, Bisen PS, Tyagi RK. RNA-loaded dendritic cells: more than a tour de force in cancer therapeutics. Immunotherapy. 2019;11:1129\u201347.","journal-title":"Immunotherapy."},{"key":"791_CR12","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1007\/s11033-008-9429-7","volume":"36","author":"S He","year":"2009","unstructured":"He S, Zhang D, Cheng F, Gong F, Guo Y. Applications of RNA interference in cancer therapeutics as a powerful tool for suppressing gene expression. Mol Biol Rep. 2009;36:2153\u201363.","journal-title":"Mol Biol Rep."},{"key":"791_CR13","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","volume":"27","author":"ST Crooke","year":"2018","unstructured":"Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA-targeted therapeutics. Cell Metab. 2018;27:714\u201339.","journal-title":"Cell Metab"},{"key":"791_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1056\/NEJMra1705346","volume":"380","author":"AA Levin","year":"2019","unstructured":"Levin AA. Treating disease at the RNA level with oligonucleotides. N Engl J Med. 2019;380:57\u201370.","journal-title":"N Engl J Med"},{"key":"791_CR15","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nbt.3589","volume":"34","author":"XH Liang","year":"2016","unstructured":"Liang XH, Shen W, Sun H, Migawa MT, Vickers TA, Crooke ST. Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames. Nat Biotechnol. 2016;34:875\u201380.","journal-title":"Nat Biotechnol"},{"key":"791_CR16","doi-asserted-by":"publisher","first-page":"9645","DOI":"10.1021\/acs.jmedchem.6b00551","volume":"59","author":"WB Wan","year":"2016","unstructured":"Wan WB, Seth PP. The medicinal chemistry of therapeutic oligonucleotides. J Med Chem. 2016;59:9645\u201367.","journal-title":"J Med Chem"},{"key":"791_CR17","first-page":"468","volume":"292","author":"S Henry","year":"2000","unstructured":"Henry S, Stecker K, Brooks D, Monteith D, Conklin B, Bennett CF. Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J Pharm Exp Ther. 2000;292:468\u201379.","journal-title":"J Pharm Exp Ther"},{"key":"791_CR18","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/gt.2017.34","volume":"24","author":"NN Singh","year":"2017","unstructured":"Singh NN, Howell MD, Androphy EJ, Singh RN. How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy. Gene Ther. 2017;24:520\u20136.","journal-title":"Gene Ther"},{"key":"791_CR19","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","volume":"376","author":"KK Ray","year":"2017","unstructured":"Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376:1430\u201340.","journal-title":"N Engl J Med"},{"key":"791_CR20","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1208760","volume":"369","author":"T Coelho","year":"2013","unstructured":"Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369:819\u201329.","journal-title":"N Engl J Med"},{"key":"791_CR21","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723\u201332.","journal-title":"N Engl J Med"},{"key":"791_CR22","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","volume":"388","author":"NJ Viney","year":"2016","unstructured":"Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet. 2016;388:2239\u201353.","journal-title":"Lancet."},{"key":"791_CR23","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1405760","volume":"372","author":"HR Buller","year":"2015","unstructured":"Buller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015;372:232\u201340.","journal-title":"N Engl J Med"},{"key":"791_CR24","doi-asserted-by":"publisher","first-page":"5772","DOI":"10.1182\/blood-2011-07-366633","volume":"119","author":"N Mimura","year":"2012","unstructured":"Mimura N, Fulciniti M, Gorgun G, Tai YT, Cirstea D, Santo L, et al. Blockade of XBP1 splicing by inhibition of IRE1alpha is a promising therapeutic option in multiple myeloma. Blood. 2012;119:5772\u201381.","journal-title":"Blood."},{"key":"791_CR25","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1182\/blood-2004-09-3704","volume":"105","author":"JJ Keats","year":"2005","unstructured":"Keats JJ, Maxwell CA, Taylor BJ, Hendzel MJ, Chesi M, Bergsagel PL, et al. Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients. Blood. 2005;105:4060\u20139.","journal-title":"Blood"},{"key":"791_CR26","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1182\/blood.V92.9.3025","volume":"92","author":"M Chesi","year":"1998","unstructured":"Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH\/MMSET hybrid transcripts. Blood. 1998;92:3025\u201334.","journal-title":"Blood."},{"key":"791_CR27","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1182\/blood-2003-11-4079","volume":"104","author":"CA Maxwell","year":"2004","unstructured":"Maxwell CA, Rasmussen E, Zhan F, Keats JJ, Adamia S, Strachan E, et al. RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma. Blood. 2004;104:1151\u20138.","journal-title":"Blood."},{"key":"791_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/B978-0-12-800092-2.00003-4","volume":"123","author":"S Adamia","year":"2014","unstructured":"Adamia S, Kriangkum J, Belch AR, Pilarski LM. Aberrant posttranscriptional processing of hyaluronan synthase 1 in malignant transformation and tumor progression. Adv Cancer Res. 2014;123:67\u201394.","journal-title":"Adv Cancer Res"},{"key":"791_CR29","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2174\/1568009611313040001","volume":"13","author":"S Adamia","year":"2013","unstructured":"Adamia S, Pilarski PM, Belch AR, Pilarski LM. Aberrant splicing, hyaluronan synthases and intracellular hyaluronan as drivers of oncogenesis and potential drug targets. Curr Cancer Drug Targets. 2013;13:347\u201361.","journal-title":"Curr Cancer Drug Targets"},{"key":"791_CR30","doi-asserted-by":"publisher","first-page":"4836","DOI":"10.1182\/blood-2004-10-3825","volume":"105","author":"S Adamia","year":"2005","unstructured":"Adamia S, Reiman T, Crainie M, Mant MJ, Belch AR, Pilarski LM. Intronic splicing of hyaluronan synthase 1 (HAS1): a biologically relevant indicator of poor outcome in multiple myeloma. Blood. 2005;105:4836\u201344.","journal-title":"Blood."},{"key":"791_CR31","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1182\/blood-2013-02-481507","volume":"123","author":"S Adamia","year":"2014","unstructured":"Adamia S, Bar-Natan M, Haibe-Kains B, Pilarski PM, Bach C, Pevzner S, et al. NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML. Blood. 2014;123:2816\u201325.","journal-title":"Blood."},{"key":"791_CR32","doi-asserted-by":"publisher","first-page":"4478","DOI":"10.1182\/blood-2002-06-1647","volume":"100","author":"S Spena","year":"2002","unstructured":"Spena S, Duga S, Asselta R, Malcovati M, Peyvandi F, Tenchini ML. Congenital afibrinogenemia: first identification of splicing mutations in the fibrinogen Bbeta-chain gene causing activation of cryptic splice sites. Blood. 2002;100:4478\u201384.","journal-title":"Blood."},{"key":"791_CR33","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41408-021-00554-9","volume":"11","author":"S Talluri","year":"2021","unstructured":"Talluri S, Samur MK, Buon L, Kumar S, Potluri LB, Shi J, et al. Dysregulated APOBEC3G causes DNA damage and promotes genomic instability in multiple myeloma. Blood Cancer J. 2021;11:166.","journal-title":"Blood Cancer J"},{"key":"791_CR34","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1182\/blood.V93.5.1684","volume":"93","author":"M Crainie","year":"1999","unstructured":"Crainie M, Belch AR, Mant MJ, Pilarski LM. Overexpression of the receptor for hyaluronan-mediated motility (RHAMM) characterizes the malignant clone in multiple myeloma: identification of three distinct RHAMM variants. Blood. 1999;93:1684\u201396.","journal-title":"Blood"},{"key":"791_CR35","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1371\/journal.pgen.0030099","volume":"3","author":"J Hull","year":"2007","unstructured":"Hull J, Campino S, Rowlands K, Chan MS, Copley RR, Taylor MS, et al. Identification of common genetic variation that modulates alternative splicing. PLoS Genet. 2007;3:e99.","journal-title":"PLoS Genet"},{"key":"791_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5698","volume":"5","author":"J Monlong","year":"2014","unstructured":"Monlong J, Calvo M, Ferreira PG, Guigo R. Identification of genetic variants associated with alternative splicing using sQTLseekeR. Nat Commun. 2014;5:4698.","journal-title":"Nat Commun"},{"key":"791_CR37","doi-asserted-by":"publisher","first-page":"73960","DOI":"10.18632\/oncotarget.12170","volume":"7","author":"Y Willemen","year":"2016","unstructured":"Willemen Y, Van den Bergh JM, Bonte SM, Anguille S, Heirman C, Stein BM, et al. The tumor-associated antigen RHAMM (HMMR\/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells. Oncotarget. 2016;7:73960\u201370.","journal-title":"Oncotarget."},{"key":"791_CR38","doi-asserted-by":"publisher","first-page":"84847","DOI":"10.18632\/oncotarget.11215","volume":"8","author":"M Schmitt","year":"2017","unstructured":"Schmitt M, Huckelhoven AG, Hundemer M, Schmitt A, Lipp S, Emde M, et al. Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial. Oncotarget. 2017;8:84847\u201362.","journal-title":"Oncotarget."},{"key":"791_CR39","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1007\/s10517-015-3041-3","volume":"159","author":"NP Akent\u2019eva","year":"2015","unstructured":"Akent\u2019eva NP, Shushanov SS, Kotel\u2019nikov AI. Effects of RHAMM\/HMMR-selective peptides on survival of breast cancer cells. Bull Exp Biol Med. 2015;159:658\u201361.","journal-title":"Bull Exp Biol Med"},{"key":"791_CR40","doi-asserted-by":"publisher","first-page":"4593","DOI":"10.21873\/anticanres.12764","volume":"38","author":"MH Yeh","year":"2018","unstructured":"Yeh MH, Tzeng YJ, Fu TY, You JJ, Chang HT, Ger LP, et al. Extracellular matrix-receptor interaction signaling genes associated with inferior breast cancer survival. Anticancer Res. 2018;38:4593\u2013605.","journal-title":"Anticancer Res"},{"key":"791_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-019-02173-2","volume":"17","author":"L Zhang","year":"2019","unstructured":"Zhang L, Zhang Z, Yu Z. Identification of a novel glycolysis-related gene signature for predicting metastasis and survival in patients with lung adenocarcinoma. J Transl Med. 2019;17:423.","journal-title":"J Transl Med"},{"key":"791_CR42","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1158\/1541-7786.MCR-19-0877","volume":"18","author":"S Ye","year":"2020","unstructured":"Ye S, Liu Y, Fuller AM, Katti R, Ciotti GE, Chor S, et al. TGFbeta and hippo pathways cooperate to enhance sarcomagenesis and metastasis through the hyaluronan-mediated motility receptor (HMMR). Mol Cancer Res. 2020;18:560\u201373.","journal-title":"Mol Cancer Res"},{"key":"791_CR43","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.omtn.2017.02.001","volume":"7","author":"ME Ostergaard","year":"2017","unstructured":"Ostergaard ME, Nichols J, Dwight TA, Lima W, Jung ME, Swayze EE, et al. Fluorinated nucleotide modifications modulate allele selectivity of SNP-targeting antisense oligonucleotides. Mol Ther Nucleic Acids. 2017;7:20\u201330.","journal-title":"Mol Ther Nucleic Acids"},{"key":"791_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/gb4150","volume":"15","author":"T Sterne-Weiler","year":"2014","unstructured":"Sterne-Weiler T, Sanford JR. Exon identity crisis: disease-causing mutations that disrupt the splicing code. Genome Biol. 2014;15:201.","journal-title":"Genome Biol"},{"key":"791_CR45","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.celrep.2016.08.071","volume":"17","author":"JP Ling","year":"2016","unstructured":"Ling JP, Chhabra R, Merran JD, Schaughency PM, Wheelan SJ, Corden JL, et al. PTBP1 and PTBP2 repress nonconserved cryptic exons. Cell Rep. 2016;17:104\u201313.","journal-title":"Cell Rep."},{"key":"791_CR46","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s00439-017-1791-x","volume":"136","author":"AG Jacob","year":"2017","unstructured":"Jacob AG, Smith CWJ. Intron retention as a component of regulated gene expression programs. Hum Genet. 2017;136:1043\u201357.","journal-title":"Hum Genet"},{"key":"791_CR47","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1038\/ng.3414","volume":"47","author":"H Jung","year":"2015","unstructured":"Jung H, Lee D, Lee J, Park D, Kim YJ, Park WY, et al. Intron retention is a widespread mechanism of tumor-suppressor inactivation. Nat Genet. 2015;47:1242\u20138.","journal-title":"Nat Genet"},{"key":"791_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2013.47","volume":"3","author":"X He","year":"2014","unstructured":"He X, Arslan AD, Ho TT, Yuan C, Stampfer MR, Beck WT. Involvement of polypyrimidine tract-binding protein (PTBP1) in maintaining breast cancer cell growth and malignant properties. Oncogenesis. 2014;3:e84.","journal-title":"Oncogenesis."},{"key":"791_CR49","doi-asserted-by":"publisher","first-page":"e0170991","DOI":"10.1371\/journal.pone.0170991","volume":"12","author":"B Kaya","year":"2017","unstructured":"Kaya B, Goceri E, Becker A, Elder B, Puduvalli V, Winter J, et al. Automated fluorescent miscroscopic image analysis of PTBP1 expression in glioma. PLoS ONE. 2017;12:e0170991.","journal-title":"PLoS ONE"},{"key":"791_CR50","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.lfs.2014.07.038","volume":"114","author":"B Chen","year":"2014","unstructured":"Chen B, Zhao AG, Shao J, Mu XY, Jiang L, Liu JW. The effects of PTBP3 silencing on the proliferation and differentiation of MKN45 human gastric cancer cells. Life Sci. 2014;114:29\u201335.","journal-title":"Life Sci"},{"key":"791_CR51","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41590-017-0035-5","volume":"19","author":"E Monzon-Casanova","year":"2018","unstructured":"Monzon-Casanova E, Screen M, Diaz-Munoz MD, Coulson RMR, Bell SE, Lamers G, et al. The RNA-binding protein PTBP1 is necessary for B cell selection in germinal centers. Nat Immunol. 2018;19:267\u201378.","journal-title":"Nat Immunol"},{"key":"791_CR52","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","volume":"82","author":"Y Hua","year":"2008","unstructured":"Hua Y, Vickers TA, Okunola HL, Bennett CF, Krainer AR. Antisense masking of an hnRNP A1\/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet. 2008;82:834\u201348.","journal-title":"Am J Hum Genet"},{"key":"791_CR53","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1089\/nat.2017.0682","volume":"27","author":"A Aartsma-Rus","year":"2017","unstructured":"Aartsma-Rus A, Straub V, Hemmings R, Haas M, Schlosser-Weber G, Stoyanova-Beninska V, et al. Development of exon skipping therapies for Duchenne muscular dystrophy: a critical review and a perspective on the outstanding issues. Nucleic Acid Ther. 2017;27:251\u20139.","journal-title":"Nucleic Acid Ther"},{"key":"791_CR54","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1083\/jcb.201207087","volume":"199","author":"F Rigo","year":"2012","unstructured":"Rigo F, Hua Y, Krainer AR, Bennett CF. Antisense-based therapy for the treatment of spinal muscular atrophy. J Cell Biol. 2012;199:21\u20135.","journal-title":"J Cell Biol"},{"key":"791_CR55","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1609243","volume":"376","author":"K Fitzgerald","year":"2017","unstructured":"Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376:41\u201351.","journal-title":"N Engl J Med"},{"key":"791_CR56","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1056\/NEJMp1614154","volume":"376","author":"A Khvorova","year":"2017","unstructured":"Khvorova A. Oligonucleotide therapeutics\u2014a new class of cholesterol-lowering drugs. N Engl J Med. 2017;376:4\u20137.","journal-title":"N Engl J Med"},{"key":"791_CR57","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","volume":"375","author":"BA Ference","year":"2016","unstructured":"Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med. 2016;375:2144\u201353.","journal-title":"N Engl J Med"},{"key":"791_CR58","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:22\u201331.","journal-title":"N Engl J Med"},{"key":"791_CR59","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11\u201321.","journal-title":"N Engl J Med"},{"key":"791_CR60","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.18632\/aging.101958","volume":"11","author":"Y Cai","year":"2019","unstructured":"Cai Y, Sheng Z, Chen Y, Wang J. LncRNA HMMR-AS1 promotes proliferation and metastasis of lung adenocarcinoma by regulating MiR-138\/sirt6 axis. Aging. 2019;11:3041\u201354.","journal-title":"Aging"},{"key":"791_CR61","first-page":"223","volume":"8","author":"W Liu","year":"2016","unstructured":"Liu W, Ma J, Cheng Y, Zhang H, Luo W, Zhang H. HMMR antisense RNA 1, a novel long noncoding RNA, regulates the progression of basal-like breast cancer cells. Breast Cancer. 2016;8:223\u20139.","journal-title":"Breast Cancer"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00791-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00791-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00791-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T20:06:56Z","timestamp":1675541216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00791-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,3]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["791"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00791-0","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,3]]},"assertion":[{"value":"27 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KCA is on the Advisory board of Celgene, Millenium-Takeda, Gilead, Janssen, Sanofi-Aventis, and Bristol Myers Squibb, and is a Scientific Founder of Oncopep and C4 Therapeutics. DC is a consultant to Stemline Therapeutic, Inc., Oncopeptide AB, and Equity owner in C4 Therapeutics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}